Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

EIKN

Eikon Therapeutics Inc

Apr 30 • 10:39AM ET

9.39

+0.28 3.02 %

Healthcare • Biotechnology • USA • Small • NASD

Held by: VTI VXF SCHA SCHB VTWO TMED VTWG BMED VTWV VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	44.51%	Shs Outstand	54.14M	Perf Week	-12.29%
Market Cap	508.10M	Forward P/E	-	EPS next Y	-5.82	Insider Trans	13.36%	Shs Float	30.04M	Perf Month	-11.29%
Enterprise Value	1.59B	PEG	-	EPS next Q	-1.67	Inst Own	5.20%	Short Float	11.85%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	94.48%	Inst Trans	15.80%	Short Ratio	7.97	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	8.48%	ROA	-	Short Interest	3.56M	Perf YTD	-37.43%
Book/sh	-16.24	P/C	1.51	EPS next 5Y	63.98%	ROE	-	52W High	17.40 -46.06%	Perf Year	-
Cash/sh	6.21	P/FCF	-	EPS past 3/5Y	-13.35% -	ROIC	-	52W Low	7.90 18.80%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.75% 9.71%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.99	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.34	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.88	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	6.34	EPS Q/Q	-	SMA20	-6.68%	Beta	-	Target Price	25.60
Payout	-	Debt/Eq	0.91	Sales Q/Q	-	SMA50	-19.81%	Rel Volume	0.40	Prev Close	9.11
Employees	-	LT Debt/Eq	0.88	Earnings	Mar 30 BMO	SMA200	-23.00%	Avg Volume	446.71K	Price	9.39
IPO	Feb 05, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-658.43% -	Trades		Volume	38,884	Change	3.02%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-02-26	Initiated	Morgan Stanley	Overweight	$32
Mar-02-26	Initiated	Mizuho	Outperform	$26
Mar-02-26	Initiated	JP Morgan	Overweight	$29
Mar-02-26	Initiated	Cantor Fitzgerald	Overweight
Mar-02-26	Initiated	BofA Securities	Buy	$34
Feb-26-26	Initiated	Wedbush	Underperform	$7

Mar-30-26 07:48AM	Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire)
Feb-26-26 09:42AM	Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls (The Fly) -8.39%
Feb-24-26 12:02PM	Medtronic Diabetes Unit MiniMed Seeks $784 Million in US IPO (Bloomberg)
Feb-09-26 08:30AM	Wall Street Braces For IPO Boom: Goldman Says 2026 Listings Could Hit $160 Billion As Tech, AI Lead (Benzinga)
Feb-06-26 04:18PM	Jennifer Garner's Once Upon a Farm Rises Nearly 20% To Wrap Up Busy Week for IPOs (Barrons.com)
07:23PM	Loading…
Feb-05-26 07:23PM	This Mobile App Marketing Firm Is Holding Off an IPO for Now (Barrons.com)
Feb-04-26 07:59PM	Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Eikon Therapeutics is a biopharmaceutical company. It engages in the development of medicines for unmet medical needs. The company was founded in 2019 and is headquartered in Millbrae, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Column Group IV GP, LP	10% Owner	Feb 06 '26	Buy	18.00	2,117,760	38,119,680	4,312,139	Feb 09 09:19 PM
Foresite Capital Management IV	10% Owner	Feb 04 '26	Buy	18.00	55,555	999,990	1,318,983	Feb 06 07:37 PM
FRAZIER KENNETH C	Director	Feb 04 '26	Buy	18.00	111,111	1,999,998	111,111	Feb 06 06:33 PM
Wolfe Josh	Director	Feb 04 '26	Buy	18.00	277,776	4,999,968	138,888	Feb 06 06:27 PM
Lux Venture Partners V, LLC	10% Owner	Feb 04 '26	Buy	18.00	277,776	4,999,968	138,888	Feb 06 06:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EIKN

Eikon Therapeutics Inc

Upgrade your Finviz experience